12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BHCG-VAC: Phase II discontinued

Celldex disclosed in its 2Q11 earnings that in June it discontinued an open-label, U.S. Phase II trial comparing neoadjuvant therapy with CDX-1307 plus cisplatin and gemcitabine vs. cisplatin and gemcitabine alone prior to surgical resection in about 30 patients with newly diagnosed hCG-beta expressing muscle-invasive...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >